HSCT of the 29 NEMO-deficient patients
Patient . | Age at HSCT (y) . | HLA match . | Source . | MNC (×108 cells/kg) . | Conditioning regimen . | Day ANC>500 . | GVHD prophylaxis . | Donor chimerism (%) . |
---|---|---|---|---|---|---|---|---|
1 | 0.41 | MSD | PSC | 6.2 | Flu-Bu-rATG | 17 | NR | 19 |
1bis | 1.25 | MSD† | PSC | 6 | Flu-Mel-Alz | 16 | NR | 98 |
2 | 0.33 | MSD | BM | 4.03 | Flu-Bu-rATG | 19 | CsA-MMF | 85 |
3 | 0.41 | MSD | BM | NR | Flu-TBI | NR | NR | 86 |
4 | 5.4 | MSD | NR | NR | Bu-Flu-rATG | NR | Csa-CST | 100 |
5 | 5.41 | MSD* | BM/CB | 3.63 | Bu-Cy | 14 | CST-CsA | 98 |
6 | 6.33 | MSD* | BM/CB | NR | Flu-Bu-Alz | 29 | CsA | 99 |
7 | 0.75 | MSD* | BM | NR | Bu-Cy- rATG | NR | CST-CsA | 100 |
8 | 1.41 | MUD | BM | NR | Bu-Cy- rATG | None | NR | NR |
9 | 3.41 | MUD | BM | 0.25 | Bu-Cy- rATG | None | None | 65 |
9bis | 3.58 | MUD† | PSC | 0.1 | Flu | 12 | None | 100 |
10 | 4.9 | MUD | BM | 5.9 | Flu-Mel-rATG | 10 | Tacro-MMF-CST | 100 |
11 | 3.3 | MUD | BM | 6.12 | Bu-Cy-eATG | 9 | CST-CsA | 100 |
12 | 7.75 | MUD | BM | 7.2 | Bu-Cy- rATG | 11 | CST-CsA | 60 |
12bis | 12.5 | MUD† | PSC | NR | No | NR | No | 53 |
13 | 6 | MUD | BM | 6.6 | Flu-Mel-rATG | 14 | CsA-MMF | 100 |
14 | 8 | MUD | PSC | 19.2 | Flu-Mel-Alz | NR | NR | 82 |
15 | 2.4 | MUD | CB | NR | Bu-Cy- rATG | 15 | CsA-MMF | 100 |
16 | 2.1 | MUD | CB | NR | Bu-Cy-eATG | NR | CsA-MMF | 100 |
17 | 12.25 | MUD | NR | NR | Flu-Bu-rATG | NR | NR | 100 |
18 | NR | MUD | NR | NR | Bu-Cy | NR | NR | NR |
19 | 2.25 | MUD | NR | NR | NR | NR | Yes (unspecified) | 80 |
19bis | 2.5 | MUD† | PSC | NR | NR | NR | No | NR |
20 | 1 | MUD 9/10 | NR | NR | Bu-Flu-rATG | NR | Tacro-MTX | NR |
21 | 13.5 | MUD 7/8 | BM | 3.33 | Bu-Cy-eATG | 11 | CST-CsA | 100 |
22 | 18.83 | MUD 7/8 | BM | 3.94 | Bu-Cy-eATG | 14 | CST-CsA | 100 |
23 | 3.8 | MUD 5/6 | CB | 6.9 | Bu-Cy-eATG | NR | CsA-MMF | 100 |
24 | 4.5 | MUD 8/10 | BM | 5.9 | Flu-Bu-Alz | 15 | CsA-MMF | 100 |
25 | 0.62 | MUD 7/10 | CB | 1.19 | Bu-Cy-eATG | 20 | CST-CsA | 100 |
26 | 2.16 | MUD 5/8 | CB | 0.85 | Flu-Mel-rATG | 13 | Tacro-then CsA | 30 |
27 | 3 | MUD 2/6 | CB | 0.6 | Flu-Mel-rATG | 19 | MTX J1/3-tacro | 100 |
28 | 13.83 | Haplo id* | PSC | 4 | Flu-Mel-rATG | 10 | CST-CsA | NR |
29 | 0.9 | Haplo id* | BM | 13 | Flu-Bu-Alz | 37 | Cy-CsA-MMF | 100 |
Patient . | Age at HSCT (y) . | HLA match . | Source . | MNC (×108 cells/kg) . | Conditioning regimen . | Day ANC>500 . | GVHD prophylaxis . | Donor chimerism (%) . |
---|---|---|---|---|---|---|---|---|
1 | 0.41 | MSD | PSC | 6.2 | Flu-Bu-rATG | 17 | NR | 19 |
1bis | 1.25 | MSD† | PSC | 6 | Flu-Mel-Alz | 16 | NR | 98 |
2 | 0.33 | MSD | BM | 4.03 | Flu-Bu-rATG | 19 | CsA-MMF | 85 |
3 | 0.41 | MSD | BM | NR | Flu-TBI | NR | NR | 86 |
4 | 5.4 | MSD | NR | NR | Bu-Flu-rATG | NR | Csa-CST | 100 |
5 | 5.41 | MSD* | BM/CB | 3.63 | Bu-Cy | 14 | CST-CsA | 98 |
6 | 6.33 | MSD* | BM/CB | NR | Flu-Bu-Alz | 29 | CsA | 99 |
7 | 0.75 | MSD* | BM | NR | Bu-Cy- rATG | NR | CST-CsA | 100 |
8 | 1.41 | MUD | BM | NR | Bu-Cy- rATG | None | NR | NR |
9 | 3.41 | MUD | BM | 0.25 | Bu-Cy- rATG | None | None | 65 |
9bis | 3.58 | MUD† | PSC | 0.1 | Flu | 12 | None | 100 |
10 | 4.9 | MUD | BM | 5.9 | Flu-Mel-rATG | 10 | Tacro-MMF-CST | 100 |
11 | 3.3 | MUD | BM | 6.12 | Bu-Cy-eATG | 9 | CST-CsA | 100 |
12 | 7.75 | MUD | BM | 7.2 | Bu-Cy- rATG | 11 | CST-CsA | 60 |
12bis | 12.5 | MUD† | PSC | NR | No | NR | No | 53 |
13 | 6 | MUD | BM | 6.6 | Flu-Mel-rATG | 14 | CsA-MMF | 100 |
14 | 8 | MUD | PSC | 19.2 | Flu-Mel-Alz | NR | NR | 82 |
15 | 2.4 | MUD | CB | NR | Bu-Cy- rATG | 15 | CsA-MMF | 100 |
16 | 2.1 | MUD | CB | NR | Bu-Cy-eATG | NR | CsA-MMF | 100 |
17 | 12.25 | MUD | NR | NR | Flu-Bu-rATG | NR | NR | 100 |
18 | NR | MUD | NR | NR | Bu-Cy | NR | NR | NR |
19 | 2.25 | MUD | NR | NR | NR | NR | Yes (unspecified) | 80 |
19bis | 2.5 | MUD† | PSC | NR | NR | NR | No | NR |
20 | 1 | MUD 9/10 | NR | NR | Bu-Flu-rATG | NR | Tacro-MTX | NR |
21 | 13.5 | MUD 7/8 | BM | 3.33 | Bu-Cy-eATG | 11 | CST-CsA | 100 |
22 | 18.83 | MUD 7/8 | BM | 3.94 | Bu-Cy-eATG | 14 | CST-CsA | 100 |
23 | 3.8 | MUD 5/6 | CB | 6.9 | Bu-Cy-eATG | NR | CsA-MMF | 100 |
24 | 4.5 | MUD 8/10 | BM | 5.9 | Flu-Bu-Alz | 15 | CsA-MMF | 100 |
25 | 0.62 | MUD 7/10 | CB | 1.19 | Bu-Cy-eATG | 20 | CST-CsA | 100 |
26 | 2.16 | MUD 5/8 | CB | 0.85 | Flu-Mel-rATG | 13 | Tacro-then CsA | 30 |
27 | 3 | MUD 2/6 | CB | 0.6 | Flu-Mel-rATG | 19 | MTX J1/3-tacro | 100 |
28 | 13.83 | Haplo id* | PSC | 4 | Flu-Mel-rATG | 10 | CST-CsA | NR |
29 | 0.9 | Haplo id* | BM | 13 | Flu-Bu-Alz | 37 | Cy-CsA-MMF | 100 |
The “bis” for patients 1, 9, 12 and 19 corresponds to the second HSCT. MUD mismatches are specified.
Alz, alemtuzumab; ANC >500, absolute neutrophil count >500/mm3; ATG, antithymocyte globulin (e, horse; r, rabbit); BM, bone marrow stem cell graft; Bu, busulfan; CB, cord blood stem cell graft; CsA, cyclosporin A; CST, corticosteroids; Cy, cyclophosphamide; Flu, fludarabine; haplo-id, haplo-identical donor; Mel, melphalan; MMF, mycophenolate mofetil; MNC, mononuclear cell count; MTX, methotrexate; PSC, peripheral blood stem cells; Tacro, tacrolimus; TBI, total body irradiation; y, years.
Carrier sister or mother.
Same donor as for the first HSCT.